Potential Healthcare Use Cases

Scientists are using one of the most powerful computing technologies ever developed — quantum computers — to help design better cancer medicines, faster and more precisely than ever before.

The Challenge:

When doctors treat cancer, the medicines they use need to find and disable specific targets in cancer cells without harming healthy ones. Designing drugs that are this precise is incredibly difficult. It requires understanding how drug molecules interact with proteins at an almost unimaginably small scale — the scale of individual electrons.

Traditional computers, even very powerful ones, cannot fully simulate these interactions accurately. They rely on shortcuts and approximations that can lead scientists in the wrong direction, wasting years of research and billions of dollars.

The Breakthrough:

Quantum computers work differently from traditional computers. They harness the laws of quantum physics — the same laws that govern how electrons and atoms behave — making them uniquely suited to simulate drug-protein interactions with far greater accuracy than ever before possible.

Ths research team is combining quantum computers with advanced artificial intelligence to create smarter, more accurate tools for designing cancer drugs. 

The quantum computer handles the most complex chemistry calculations, and the AI learns from those results to quickly predict how new drug candidates might behave — at a tiny fraction of the time and cost of traditional methods.

What This Means for Patients:

Better computational tools mean:

• Promising cancer drug candidates can be identified faster

• Drugs can be designed to be more precise, reducing harmful side effects

• Research that once took years may be accelerated significantly

• Insights gained can be applied to many types of cancer, not just one

When Will Patients Benefit?:

Progress is already happening. The AI-powered drug design tools being developed are expected to reach the broader research community within the next few years, helping scientists make better decisions earlier in the drug discovery process.

As quantum computers continue to improve — which is happening rapidly — their role in drug design will grow even more powerful over the next decade, opening doors to discoveries that are simply not possible today.

The Bottom Line:

This research represents a new chapter in the fight against cancer — one where the most advanced computing technology available is put to work helping scientists design medicines that are smarter, safer, and more effective. It is science today building the cures of tomorrow.

Quantum-Informed Molecular Simulation for Covalent Cancer Drug Design:

An interdisciplinary team spanning quantum computing, computational chemistry, biophysics, and drug discovery is developing a novel framework that combines quantum computers with artificial intelligence to model how a promising class of cancer drugs — covalent kinase inhibitors — bind to their protein targets with unprecedented accuracy.

The Scientific Problem:

Designing covalent kinase inhibitors requires understanding extremely subtle electronic interactions that occur when a drug molecule forms a chemical bond with its protein target. These interactions are governed by quantum mechanical effects that current computational methods cannot capture with sufficient accuracy. The most widely used approach — Density Functional Theory — introduces errors that are particularly problematic for modeling chemical reactions, potentially leading researchers toward incorrect conclusions about how and how well a drug will bind. More accurate classical methods exist but become computationally impractical at the molecular scales relevant to real drug candidates.

The Core Idea:

The team's approach has two connected components working together:

• Quantum Computing generates highly accurate energy calculations for key chemical interactions — accuracy that classical computers fundamentally struggle to achieve for these types of reactions.

• Artificial Intelligence learns from those quantum-generated results and uses them to build predictive models that can then simulate full drug-protein dynamics quickly and at scales far beyond what quantum hardware alone can currently handle.

Together, these two technologies compensate for each other's limitations — quantum computing provides accuracy that AI alone cannot achieve, while AI provides the scale and speed that quantum hardware currently lacks.

How They Make It Work on Today's Hardware:

Current quantum computers are powerful but limited in size and prone to errors. The team has developed several clever strategies to work within these constraints without sacrificing meaningful accuracy:

• Breaking large molecular systems into smaller fragments that fit on current hardware, then reassembling the results

• Designing efficient quantum circuits that extract maximum information with minimum computational resources

• Using classical post-processing to dramatically reduce hardware noise, achieving accuracy levels competitive with high-end classical methods on small systems

What Has Been Demonstrated So Far:

The team has systematically tested their approach on increasingly large and complex biological systems, all run on real IBM quantum hardware:

• Successfully modeled water and used the results to train accurate AI force fields

• Modeled a biologically important phosphate reaction, resolving for the first time which of two competing chemical pathways dominates

• Performed some of the largest molecular quantum simulations to date on fragments of the ATP hydrolysis reaction — one of the most fundamental reactions in biology

• Begun quantum simulations of their primary drug target, a simplified covalent kinase inhibitor system

Honest Assessment of Current Limitations:

The team is transparent about where the work stands. For larger molecular systems, quantum results are currently more accurate than basic classical approximations but have not yet surpassed the best available classical methods. Achieving that threshold — true quantum advantage for drug-relevant molecules — remains the central open scientific question and depends on continued advances in quantum hardware over the coming years.

Expected Scientific Outcomes:

• First quantum-informed AI force fields capable of modeling reactive drug-protein dynamics

• Establishment of practical accuracy benchmarks for quantum molecular simulation on current hardware

• High-accuracy models of covalent inhibitor binding with direct implications for drug selectivity and resistance

• A generalizable computational pipeline applicable to a broad range of cancer drug targets

• Widely useful advances in quantum algorithms and machine learning methods for the broader research community

Timeline Outlook:

The near-term deliverables — completing quantum simulations of the target inhibitor system and building the first quantum-informed drug dynamics models — are well within reach given the progress already demonstrated. Achieving full quantum advantage over the best classical methods at clinically meaningful scales is a longer horizon goal, realistically requiring continued hardware advances over the next 10 to 15 years. However, the framework being developed is designed to deliver increasing scientific value at every stage of that journey, with important milestones achievable well before quantum hardware reaches full maturity.